Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Onda Website

Masanori Onda, M.D., Ph.D.

Selected Publications

1)  Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
J. Immunol. 193: 48-55, 2014.
2)  Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012.
3)  Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 108: 5742-7, 2011.
4)  Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, Hassan R, Pastan I.
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
J. Immunol. 177: 8822-34, 2006.
5)  Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I.
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Clin. Cancer Res. 12: 4225-31, 2006.
6)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
7)  Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I.
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Protein Eng. Des. Sel. 25: 1-6, 2012.
8)  Onda M.
Recombinant immunotoxins with low endotoxins for clinical and animal studies.
Methods Mol. Biol. 907: 627-43, 2012.
9)  Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R.
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.
Clin. Chem. Lab. Med. 50: 721-5, 2012.
10)  Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.
Immunotoxins with decreased immunogenicity and improved activity.
Leuk. Lymphoma. 52 Suppl 2: 87-90, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 7/14/2014.